Mark H.H. Kramer

Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial

C.A.J. van Beers, J. Hans DeVries, Susanne J. Kleijer et al. · The Lancet Diabetes & Endocrinology · 2016 · 377 citations

Type 1, Diabetes Management, Health Policy +5

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

Erik J.M. van Bommel, Marcel H.A. Muskiet, Michaël J.B. van Baar et al. · Kidney International · 2019 · 331 citations · Full text

Metabolic Syndrome, Diabetes Management, Renal Function +13

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double‐blind, placebo‐controlled study

Michael Hedenus, Magnus Adriansson, Jesús F. San Miguel et al. · British Journal of Haematology · 2003 · 325 citations · Full text

Prehospital antibiotics in the ambulance for sepsis: a multicentre, open label, randomised trial

Nadia Alam, Erick Oskam, Patricia M. Stassen et al. · The Lancet Respiratory Medicine · 2017 · 270 citations

Open Label, Antimicrobial Stewardship, Antibiotics +8

Risk factors for post‐thrombotic syndrome in patients with a first deep venous thrombosis

Lidwine W. Tick, Mark H.H. Kramer, Frits R. Rosendaal et al. · Journal of Thrombosis and Haemostasis · 2008 · 222 citations · Full text

Pulmonary Embolism, Thrombosis, Venous Disease +11